StudyID,Drug_Name,No_Arm,Randomization,Central_Random,Rand_Ratio,Random_Parallel,Random_Crossover,Random_Fact,Random_Cluster,Stratification,No_Stratification,Single_Arm,Hist_control,Blinding,Level_Blinding,Placebo_control,Active_Control,Control_Drug,Obj_Primary,No_Prim_EP,Primary_EP,Success_Criteria_Text,Primary_EP_SC,Key_Second_EP,Key_Second_EP_SC,IRC,Sample_Size,Power,Alpha,Sided,Subgroup,Interim,Timing_IA,Alpha_Spend_Func,Adaptive_Design,Consistency_Sens_Ana_PE,Consistency_Sens_Ana_SE,Post_Hoc_Ana,Intercurrent_Events,Gatekeeping_Strategy,Reg_Alignment,Fast_Track,Breakthrough,Priority_Review,Accelerated_App,Orphan_Drug,Pediatric,Rare_Disease,Reg_Audit,Consistency_MRCT
NCT02039674,Pembrolizumab; Paclitaxel; Carboplatin; Bevacizumab; Pemetrexed; Ipilimumab; Erlotinib; Gefitinib,14,Yes,,,Yes,No,No,,,,No,No,No,0,No,No,,,3,Part 2 Cohorts G+ and G-: Objective Response Rate (ORR); Part 2 Cohorts D4 and H: Objective Response Rate (ORR); All Cohorts: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT),,,Part 2 Cohorts G+ and G-: Progression-Free Survival (PFS),,,,,,,,,,,,,,,,,,,,,,,,,,
